Rhumbline Advisers Adaptimmune Therapeutics PLC Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 8,533 shares of ADAP stock, worth $1,279. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,533
Previous 18,313
53.4%
Holding current value
$1,279
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ADAP
# of Institutions
70Shares Held
116MCall Options Held
10.3KPut Options Held
0-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$4.11 Million0.57% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$3.56 Million0.26% of portfolio
-
Two Seas Capital LP Rye, NY22.6MShares$3.39 Million0.1% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$2.56 Million0.34% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.81MShares$721,4512.66% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $24.5M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...